Branded

RIDGEFIELD, Conn. Drug maker Boehringer Ingelheim and the Latino Commission on AIDS have launched a website targeted at Latinos living with HIV, the two announced Thursday.

The website, MenteCuerpoHAART.com, is a Spanish-language version of an already existing English-language version, MindBodyHAART.com. The site is designed to help patients, their families and doctors understand issues affecting health care and treatment of HIV and find resources on prescribed medications and clinical trials, and communicate with medical providers.

WILMINGTON, Del. AstraZeneca is launching a new campaign focused on depression, the Anglo-Swedish drug maker said Thursday.

The campaign, “Take on Depression,” consists of a Facebook page and Twitter feed designed to provide information on bipolar depression and major depressive disorder.

LOS ANGELES Abraxis BioScience shareholders have approved an acquisition of the company by Celgene, Celgene said Wednesday.

The $3 billion acquisition will give Celgene control of Abraxis’ cancer therapies and its anti-tumor Nab technology.

SILVER SPRING, Md. The Food and Drug Administration approved a drug to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

Vivitrol is an extended-release formulation of naltrexone -- which works to block opioid receptors in the brain -- administered by intramuscular injection once a month. It only is administered by a physician.

NEW YORK A weight management services provider and a drug maker are teaming up to fight obesity.

PALO ALTO, Calif. The Food and Drug Administration has turned down an application from a company seeking approval for a drug to treat fibromyalgia.

Jazz Pharmaceuticals announced Monday that the FDA had given it a complete response letter for the drug JZP-6 (sodium oxybate), citing a need for additional clinical studies and issues concerning the appropriate patient population, ensuring safe use, a proposed risk evaluation and mitigation strategy, and others.

NEW YORK Pfizer will buy King Pharmaceuticals for $3.6 billion, Pfizer said Tuesday.

The world’s largest drug maker announced that it had agreed to acquire Bristol, Tenn.-based King for $14.25 per share, which it said was a 40% premium over the Monday closing price of King’s stock.

BASEL, Switzerland Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C, Roche said.

The company announced Thursday that it had purchased global development and commercialization rights to the drug RG7227/ITMN-191 (danoprevir) from InterMune for $175 million.

Roche said the drug had shown promise in preclinical and early clinical development. The two companies have been developing the drug since 2006.